human serelaxin protein

Also Known As:

serelaxin protein, human; recombinant human relaxin-2

Networked: 18 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - human serelaxin protein: 18
- Peptides: 82426
  - Peptide Hormones: 1347
    - Relaxin: 785
      - human serelaxin protein: 18
Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Peptide Hormones: 1347
    - Relaxin: 785
      - human serelaxin protein: 18
  - Gonadal Hormones: 716
    - Corpus Luteum Hormones: 1
      - Relaxin: 785
        human serelaxin protein: 18

Experts

1.	Bani, Daniele: 3 articles (01/2019 - 01/2016)
2.	Dahlke, Marion: 3 articles (11/2018 - 04/2015)
3.	Pang, Yinuo: 3 articles (11/2018 - 04/2015)
4.	Denton, Kate M: 2 articles (02/2020 - 11/2019)
5.	Han, Lei: 2 articles (02/2020 - 11/2019)
6.	Samuel, Chrishan S: 2 articles (02/2020 - 11/2019)
7.	Shen, Matthew: 2 articles (02/2020 - 11/2019)
8.	Wang, Yan: 2 articles (02/2020 - 11/2019)
9.	Widdop, Robert E: 2 articles (02/2020 - 11/2019)
10.	Boccalini, Giulia: 2 articles (05/2016 - 01/2016)

Related Diseases

1.	Heart Failure 01/01/2020 - "An understanding of the multitude of cardioprotective actions prompted the study of serelaxin, recombinant human relaxin-2, for the treatment of acute heart failure. " 01/05/2013 - "Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial." 06/01/2018 - "Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis." 01/01/2018 - "Serelaxin is a novel recombinant human relaxin-2 that has been investigated for the treatment of acute heart failure. " 01/01/2016 - "Serelaxin, recombinant human relaxin-2, modulates endothelial vasodilatory functionality and is under evaluation for treatment of acute heart failure. "
2.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2019 - "Recombinant human relaxin-2, serelaxin, is being proved as a novel drug with therapeutic efficacy in some cardiovascular diseases, especially heart failure, a disease whose physiopathology and course are firmly correlated with important alterations in cardiac metabolism. "
3.	Fibrosis (Cirrhosis) 01/01/2023 - "Recombinant Human Relaxin-2 (RLX), a peptide agent with anti-remodeling and anti-fibrotic effects, is a promising biotherapeutic candidate for musculoskeletal fibrosis. " 02/14/2020 - "In the current study, the antifibrotic effects of recombinant human relaxin-2 (serelaxin; RLX) and/or the AT2R agonist CGP42112 (CGP) were compared with those of the established AT1R antagonist, candesartan cilexetil (CAND), in a high salt-induced cardiac fibrosis model. " 11/01/2019 - "Recombinant human relaxin-2 (serelaxin), which has organ-protective actions mediated via its cognate G protein-coupled receptor relaxin family peptide receptor 1 (RXFP1), has emerged as a potential agent to treat fibrosis. "
4.	Pre-Eclampsia (Preeclampsia) 12/01/2016 - "Therefore, the goal of this study was to test the hypothesis that recombinant human relaxin-2 (Serelaxin, Novartis; RLX) could reduce mean arterial pressure (MAP) and improve uterine artery resistance index (UARI) and nitric oxide bioavailability, and/or decrease prepro-endothelin-1 (PPET-1), soluble fms-like tyrosine kinase-1 (sFlt-1), and TNF-α) in the reduced uterine perfusion pressure (RUPP) model of preeclampsia. "
5.	Vascular System Injuries 05/01/2016 - "Protection from cigarette smoke-induced vascular injury by recombinant human relaxin-2 (serelaxin)."

Related Drugs and Biologics

1.	Tyrosine (L-Tyrosine)
2.	Salts
3.	Nitric Oxide (Nitrogen Monoxide)
4.	candesartan cilexetil (Amias)
5.	CGP 42112A
6.	Peptides (Polypeptides)
7.	Hormones (Hormone)
8.	Inflammasomes
9.	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)
10.	Peptide Receptors (Peptide Receptor)

Related Therapies and Procedures

1.	Therapeutics